Close Menu

NEW YORK ─ Infectious disease point-of-care diagnostic test company Talis Biomedical on Friday filed with the US Securities and Exchange Commission to go public on the Nasdaq.

Menlo Park, California-based Talis has not priced the offering but said in its Form S-1 that it plans to sell about 42.7 million shares of its Series 1 convertible preferred stock. The firm said that underwriters for the deal have a 30-day option to purchase additional shares of common stock.

JP Morgan, Bank of America Securities, and Piper Sandler are the joint bookrunners on the deal.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.